Skip to the line map
Before the Needle

PRP for Achilles Tendinopathy: What Does the Evidence Say?

  • Updated November 14, 2026
  • Stop 2 of 4 on the PRP injections line

Compared with placebo, platelet-rich plasma (PRP) injections have not been shown to improve Achilles tendinopathy. A 2026 meta-analysis of four placebo-controlled randomized trials (337 participants in the main function analysis) found no statistically significant PRP advantage on the VISA-A score at 3 or 6 months. A large single trial, published in JAMA in 2021 with 240 participants, tested one injection in chronic midportion tendinopathy, so its result applies most directly to that regimen and that location. A 2026 review in Frontiers in Medicine notes that the pivotal sham-controlled evidence concerns chronic midportion disease and that applying it to insertional Achilles tendinopathy calls for caution. Whether repeated injections would perform differently is an open question, not an established benefit.

What is Achilles tendinopathy?

Achilles tendinopathy is persistent pain and reduced function in the Achilles tendon related to load, such as running or jumping. It comes in two main forms:

  • Midportion tendinopathy, felt in the body of the tendon a few centimeters above where it attaches to the heel
  • Insertional tendinopathy, felt where the tendon attaches to the heel bone

They are distinct conditions at different sites and are often studied separately. Results from midportion trials should not be assumed to apply to insertional disease. Tendinopathy is also different from a tendon rupture, which is a tear. The terms used for tendon problems are explained in tendinitis vs. tendinosis.

How is PRP proposed to work?

The rationale is delivery: a concentrate of your own platelets, which carry growth factors that take part in normal repair, placed directly at the painful part of the tendon in the hope of supporting a stalled healing response. That is biologically plausible. Plausibility is not evidence of benefit, which is why placebo-controlled trials are the deciding evidence.

What have placebo-controlled trials found?

A large sham-controlled trial. The 2021 randomized clinical trial in JAMA enrolled 240 adults with midportion Achilles pain lasting more than three months, at 24 UK National Health Service hospital trusts. Participants received either one PRP injection or a sham procedure in which a needle was placed under the skin but not into the tendon. At six months, the primary outcome, the VISA-A score, averaged 54.4 in the PRP group and 53.4 in the sham group; the adjusted difference was −2.7 points (95% confidence interval −8.8 to 3.3), not statistically significant. The authors concluded their findings did not support PRP for chronic midportion Achilles tendinopathy.

The VISA-A is a 0 to 100 questionnaire on pain and function in the Achilles, where higher scores are better.

The 2026 pooled analysis. A systematic review and meta-analysis in The Journal of Foot and Ankle Surgery, published online April 15, 2026, reports in its abstract that four randomized controlled trials with 337 patients contributed VISA-A scores at 3 and 6 months, with no statistically significant difference between PRP and placebo at either point; the authors found no significant clinical or radiological benefit. A ReachMD summary from May 2026 adds that the review searched the literature through January 2025 and included four placebo-controlled randomized trials (five reports, two from the same trial). Together, the abstract and the summary report:

Outcome Participants analyzed Result vs. placebo
VISA-A function at 3 and 6 months 337 No statistically significant difference
Pain (VAS), three studies 283 at 3 months, 270 at 6 months No significant difference
Tendon thickness and vascularity on imaging, two studies Not reported in the summary No significant between-group change

According to the ReachMD summary, the authors described the evidence as single autologous PRP injections compared with placebo and said they do not recommend PRP to manage Achilles tendinopathy. They added that multiple injections might warrant study in adequately powered trials. That suggestion is a hypothesis for future research; the pooled placebo data do not show that multiple injections work.

Two cautions when reading the pooled result. First, the summary does not list each included trial’s number of injections or whether it studied midportion or insertional disease. Of the trials discussed in this article, only the 2021 JAMA trial is confirmed as a single-injection, midportion study, so the pooled result should not be read as covering every injection schedule or tendon location. Second, four trials is a small evidence base, and trials of very different sizes can contribute very different weight to a pooled estimate, so the result should not be treated as four equally weighted confirmations.

What do systematic reviews conclude, and where do they disagree?

Earlier reviews reached similar conclusions. A 2025 meta-analysis in Clinical Orthopaedics and Related Research found no VISA-A benefit for PRP over placebo at 3 months, 6 months or 1 year, and noted possible publication bias that could inflate apparent benefits in the wider literature. A 2018 meta-analysis in Clinical Orthopaedics and Related Research, in which every participant did eccentric exercise plus either PRP or saline, found no statistically significant additional benefit from PRP compared with saline on VISA-A, tendon thickness or Doppler activity. This article does not repeat its trial and participant totals, because the early Achilles PRP literature contains repeat reports of one trial: a 2011 one-year follow-up and the 2010 six-month report come from the same Dutch randomized trial, and a review that counts both as separate trials overstates the evidence.

Where reviews differ, the differences can come from study selection, whether non-placebo comparators are included, whether rupture studies are mixed in with tendinopathy, and the PRP preparation used. Reviews that mix tendon ruptures with tendinopathy or include non-placebo controls answer a different question from the placebo trials above.

What does the evidence say about exercise-based rehabilitation?

Exercise-based rehabilitation is evaluated on its own evidence, not as a head-to-head contest with PRP. In several placebo trials, both groups also received exercise-based care; the 2018 meta-analysis included only trials of that design. Those trials test what PRP adds to rehabilitation, not whether it replaces it.

For midportion Achilles tendinopathy, the Academy of Orthopaedic Physical Therapy’s 2024 clinical practice guideline, published in the Journal of Orthopaedic & Sports Physical Therapy, centers on exercise and load management. It is specific to midportion disease and is not a trial comparing PRP with exercise. Practical elements typically discussed with a clinician include adjusting training load, progressive strengthening of the calf, sticking with the program over weeks to months, and criteria for when to escalate care if symptoms are not improving.

When does Achilles pain need prompt assessment?

Seek prompt medical assessment for:

  • a sudden pop or snap at the back of the ankle, especially during activity
  • sudden inability to push off, rise on tiptoe or walk normally
  • a visible gap or marked swelling in the tendon after an injury

These can signal a tendon rupture, which needs a different evaluation from tendinopathy. Do not try to diagnose a rupture yourself.

Does PRP repair Achilles tendon tissue? Pooled evidence has not established a consistent clinical benefit for PRP over placebo. One small 2017 randomized trial in 60 men, which added four PRP injections given 14 days apart to eccentric exercise, reported more favorable results than sham, but a single small trial of a repeated-injection protocol does not establish a reliable benefit across patients or protocols. The imaging measures reported in the 2026 pooled analysis showed no significant change in tendon thickness or vascularity compared with placebo.

Are insertional and midportion Achilles problems the same? No. They occur at different locations, are often studied separately, and evidence from one should not be assumed to apply to the other. PRP’s safety profile, which also differs by site, is described in the risks and side effects of PRP injections.

Every stop on the PRP injections line

  1. Does PRP Help Tennis Elbow? What Clinical Trials Show
  2. PRP for Achilles Tendinopathy: What Does the Evidence Say?
  3. PRP vs. Hyaluronic Acid Injections for Knee Osteoarthritis: What Does Research Show?
  4. What Are the Risks and Side Effects of PRP Injections?

Reader comments

Leave a note on this stop

Your email address will not be published. Required fields are marked *